Anti-Arthritic Properties Found in Resolvin D1

A lipid mediator known as resolvin D1 demonstrated anti-arthritis properties in mice models, according to findings published in the Journal of Clinical Investigation Insight.

Researchers from Queen Mary University of London studied the properties of the lipid mediator resolvin D1 in mice models in order to test their effectiveness in resolving inflammation in rheumatoid arthritis patients. The researchers compared mice fed standard diets to those fed omega 3 enriched diets in order to directly assess resolvin D1. The investigators found that resolvin D1 is elevated in joint fluids of both mice models and human arthritis patients.

In their paper, the researchers noted that chronic inflammatory diseases such as arthritis may continue due to the failure of resolution responses. Plus, they said, current treatment strategies try to intervene early while trying to maintain joint integrity.

“Although current therapeutics have revolutionized the management of rheumatoid arthritis, existing treatments aimed at limiting joint inflammation are associated with unwanted side effects including gastrointestinal disturbances and increased risk of infections,” the study authors wrote. “In addition, although current therapeutics may lead to significant improvement in patient prognosis by slowing or stopping disease progression, treatment rarely repairs joint damage.”

When the researchers administered resolvin D1 into mice models, inflammatory arthritis was significantly reduced disease and promoted remission, they reported. Additionally, resolvin D1 promoted the expression of genes linked to cartilage repair as well as reduced the factors linked to joint damage.

“We defined bioactions for this proresolving endogenous lipid mediator in the context of joint inflammation and chondroprotection,” the study authors concluded. “Together, these results give the foundation for the development of innovative therapeutic strategies to avert joint destruction during RA with limited side effects, ultimately for the benefit of the patients.”

The researchers believe their findings warrant future investigation, especially exploring resolvin D1 as a therapeutic strategy for the treatment of rheumatoid arthritis and other inflammatory arthropathies.